News & Updates

Diabetic kidney disease (DKD) is a global healthcare burden. At a symposium co-organized by Diabetes Hongkong and Hong Kong Society of Nephrology, Professor Ronald Ma of the Chinese University of Hong Kong discussed the current landscape of DKD in Hong Kong, and Dr Masayuki Yamanouchi, a specialist in nephrology from Toranomon Hospital in Tokyo, Japan, discussed clinical and real-world evidence on the effects of a nonsteroidal mineralocorticoid receptor antagonist (MRA), finerenone, in improving outcomes in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). Dr Yamanouchi also presented two patient cases to illustrate the clinical benefits of finerenone in DKD patients with different disease severity.

Among people with cardiometabolic diseases (CMD), diets with lower inflammatory potential contribute to larger gray matter and smaller white matter hyperintensity volumes, as well as reduced risk of dementia, according to a study.

Individuals with type 2 diabetes (T2D) treated in routine clinical care appear to fare better with glucagon-like peptide-1 receptor agonists (GLP-1RAs) than with dipeptidyl peptidase-4 inhibitors (DPP-4is), with GLP-1Ras being associated with lower rates of hyperkalemia and renin-angiotensin system inhibitor (RASi) medication discontinuation, as shown in an observational study.

The incidence of cirrhosis and hepatocellular carcinoma (HCC) among veterans differs according to demographic and clinical characteristics, with the lowest rate seen among Asians, reports a study.